{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:47:31Z","timestamp":1793281651121,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.euroneuro.2011.08.005","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T21:03:54Z","timestamp":1315688634000},"page":"165-182","source":"Crossref","is-referenced-by-count":122,"title":["Clozapine resistance: Augmentation strategies"],"prefix":"10.1016","volume":"22","author":[{"given":"Stefano","family":"Porcelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Balzarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2011.08.005_bb0005","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4088\/JCP.v67n1211","article-title":"A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition","volume":"67","author":"Akdede","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0010","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1176\/ajp.151.7.1096b","article-title":"Treatment of clozapine-induced obsessive\u2013compulsive symptoms with sertraline","volume":"151","author":"Allen","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0015","first-page":"484","article-title":"Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia","volume":"41","author":"al-Semaan","year":"1996","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4088\/JCP.v66n0109","article-title":"A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety","volume":"66","author":"Anil Yagcioglu","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2007-993209","article-title":"Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial","volume":"41","author":"Assion","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1202266","article-title":"Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review","volume":"42","author":"Bachmann","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1017\/S1461145703003870","article-title":"Safety and efficacy of combined clozapine\u2013lithium pharmacotherapy","volume":"7","author":"Bender","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1745017901006010030","article-title":"Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study","volume":"6","author":"Benedetti","year":"2010","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.1017","article-title":"Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial","volume":"24","author":"Berk","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1192\/bjp.169.2.253b","article-title":"Should the administration of ECT during clozapine therapy be contraindicated?","volume":"169","author":"Bloch","year":"1996","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/schbul\/16.4.551","article-title":"Defining treatment refractoriness in schizophrenia","volume":"16","author":"Brenner","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0060","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1176\/ajp.153.12.1625","article-title":"Fluoxetine augmentation of clozapine treatment in patients with schizophrenia","volume":"153","author":"Buchanan","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0065","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","article-title":"When symptoms persist: clozapine augmentation strategies","volume":"27","author":"Buckley","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0070","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/ajp.152.6.827","article-title":"Patient response and resource management: another view of clozapine treatment of schizophrenia","volume":"152","author":"Carpenter","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0893-133X(00)00115-9","article-title":"Mazindol treatment of negative symptoms","volume":"23","author":"Carpenter","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0080","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","article-title":"Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial","volume":"69","author":"Chang","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0090","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.154.9.1243","article-title":"Time to clozapine response in a standardized trial","volume":"154","author":"Conley","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0095","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.pnpbp.2010.03.022","article-title":"Successful augmentation of clozapine-resistant treatment of schizophrenia with clonidine","volume":"34","author":"Dardennes","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4088\/JCP.v62n0210f","article-title":"Addition of risperidone to clozapine therapy in chronically psychotic inpatients","volume":"62","author":"de Groot","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0105","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"de Lucena","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1037\/1064-1297.15.6.563","article-title":"Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine","volume":"15","author":"Delle Chiaie","year":"2007","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.schres.2007.12.482","article-title":"Gabapentin for ultra resistant schizophrenia with aggressive behavior","volume":"100","author":"Demily","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.jcp.0000165740.22377.6d","article-title":"Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results","volume":"25","author":"Diaz","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/026988110101500409","article-title":"Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study","volume":"15","author":"Dursun","year":"2001","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0130","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1176\/appi.ajp.159.9.1596","article-title":"Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia","volume":"159","author":"Emsley","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/JCP.0b013e3181e5c095","article-title":"Augmentation with pregabalin in schizophrenia","volume":"30","author":"Englisch","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0140","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0145","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0893-133X(02)00319-6","article-title":"Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia","volume":"27","author":"Fabrazzo","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/archpsyc.56.1.13","article-title":"Glycine agonists: what can they teach us about schizophrenia?","volume":"56","author":"Farber","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0155","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/appi.ajp.158.12.2071","article-title":"A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia","volume":"158","author":"Fenton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00124509-199812000-00001","article-title":"ECT and clozapine in schizophrenia","volume":"14","author":"Fink","year":"1998","journal-title":"J. ECT"},{"issue":"Suppl B","key":"10.1016\/j.euroneuro.2011.08.005_bb0165","first-page":"78","article-title":"Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects","volume":"55","author":"Fleischhacker","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0170","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00004714-199712000-00014","article-title":"Prolongation of clozapine-induced granulocytopenia associated with olanzapine","volume":"17","author":"Flynn","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0175","first-page":"176","article-title":"Combined clozapine and electroconvulsive therapy","volume":"9","author":"Frankenburg","year":"1993","journal-title":"Convuls. Ther."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","article-title":"Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations","volume":"106","author":"Freudenreich","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0185","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.12.030","article-title":"Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial","volume":"92","author":"Freudenreich","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0190","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","article-title":"Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial","volume":"70","author":"Freudenreich","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0195","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0006-3223(97)00227-8","article-title":"Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine","volume":"42","author":"Friedman","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jpsychires.2009.11.004","article-title":"Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment","volume":"44","author":"Giegling","year":"2010","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0205","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"d-cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0215","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00004714-200110000-00005","article-title":"A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia","volume":"21","author":"Goff","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0220","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/jcp.0b013e31815abf34","article-title":"Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials","volume":"27","author":"Goff","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0225","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","article-title":"A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia","volume":"33","author":"Goff","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The \u2018atypicality\u2019 of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Grunder","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10401239809148944","article-title":"Olanzapine augmentation of clozapine","volume":"10","author":"Gupta","year":"1998","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0240","first-page":"395","article-title":"Risperidone as an adjunct to clozapine therapy in chronic schizophrenics","volume":"57","author":"Henderson","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0245","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.1106","article-title":"Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered","volume":"25","author":"Hindmarch","year":"2010","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0260","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0920-9964(97)00151-5","article-title":"The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia","volume":"30","author":"Horrobin","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0270","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2005-837772","article-title":"Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms","volume":"38","author":"Kampf","year":"2005","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 9","key":"10.1016\/j.euroneuro.2011.08.005_bb0280","first-page":"35","article-title":"Treatment-resistant schizophrenic patients","volume":"57","author":"Kane","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0285","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0290","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11126-006-7963-9","article-title":"Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia","volume":"77","author":"Kelly","year":"2006","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0295","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00406-004-0517-y","article-title":"Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia \u2014 an open label study","volume":"254","author":"Kho","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0300","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archpsyc.58.2.165","article-title":"A separate disease within the syndrome of schizophrenia","volume":"58","author":"Kirkpatrick","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0305","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.eurpsy.2004.12.007","article-title":"Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review","volume":"20","author":"Kontaxakis","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopsych.2004.06.029","article-title":"Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia","volume":"56","author":"Kremer","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0320","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00002826-200001000-00003","article-title":"Combined electroconvulsive-clozapine therapy","volume":"23","author":"Kupchik","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0325","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0030-1254089","article-title":"Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone","volume":"43","author":"Kuwilsky","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0330","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia","volume":"60","author":"Lane","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0335","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-005-0020-9","article-title":"The potential role of lamotrigine in schizophrenia","volume":"181","author":"Large","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0340","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.wnf.0000159953.41769.d7","article-title":"Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy","volume":"28","author":"Lerner","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0345","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0350","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4088\/JCP.v61n0809","article-title":"Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients","volume":"61","author":"Lu","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0355","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","article-title":"Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances","volume":"65","author":"Lu","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0360","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.158.1.135b","article-title":"ECT following clozapine","volume":"158","author":"Masiar","year":"1991","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0365","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3923\/pjbs.2007.4287.4290","article-title":"Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients","volume":"10","author":"Masoudzadeh","year":"2007","journal-title":"Pak. J. Biol. Sci."},{"issue":"Suppl","key":"10.1016\/j.euroneuro.2011.08.005_bb0370","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1007\/BF00442563","article-title":"A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0375","first-page":"892","article-title":"Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients","volume":"41","author":"Meltzer","year":"1990","journal-title":"Hosp. Community Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0380","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pnpbp.2006.09.015","article-title":"Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study","volume":"31","author":"Mitsonis","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0385","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0447.2004.00356.x","article-title":"Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine","volume":"110","author":"Munro","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0390","series-title":"Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study","author":"Muscatello","year":"2011"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0395","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00124509-199809000-00002","article-title":"Neurochemical mechanisms of action of ECS: evidence from in vivo studies","volume":"14","author":"Newman","year":"1998","journal-title":"J. ECT"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0400","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","article-title":"Optimizing clozapine treatment","volume":"123","author":"Nielsen","year":"2011","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3956(01)00048-6","article-title":"A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms","volume":"36","author":"Peet","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0410","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0415","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl B","key":"10.1016\/j.euroneuro.2011.08.005_bb0420","first-page":"133","article-title":"Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia","volume":"55","author":"Potkin","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0425","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.euroneuro.2011.08.005_bb0430","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1007\/BF00442568","article-title":"Clozapine in China: a review and preview of US\/PRC collaboration","volume":"99","author":"Potter","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0435","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.155.11.1626f","article-title":"Sertraline in the treatment of clozapine-induced obsessive\u2013compulsive behavior","volume":"155","author":"Rahman","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0440","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(02)00293-1","article-title":"Augmentation of clozapine partial responders with conventional antipsychotics","volume":"60","author":"Rajarethinam","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0445","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00023210-200519100-00004","article-title":"Augmentation strategies in clozapine-resistant schizophrenia","volume":"19","author":"Remington","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0450","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/oxfordjournals.schbul.a033412","article-title":"How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia","volume":"25","author":"Rosenheck","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0455","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","article-title":"Size of burden of schizophrenia and psychotic disorders","volume":"15","author":"Rossler","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0460","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0465","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","article-title":"What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia","volume":"42","author":"Schulte","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0470","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0475","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0006-3223(96)00170-9","article-title":"Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study","volume":"40","author":"Silver","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0480","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.jcp.0000084026.22282.5f","article-title":"Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder","volume":"23","author":"Small","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0485","doi-asserted-by":"crossref","unstructured":"Sommer, I.E., Begemann, M.J., Temmerman, A., Leucht, S., 2011. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin.","DOI":"10.1093\/schbul\/sbr004"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-199805000-00009","article-title":"Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia","volume":"13","author":"Spina","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0495","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/hup.595","article-title":"Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study","volume":"19","author":"Stryjer","year":"2004","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0505","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/026988110001400411","article-title":"Refractory schizophrenia and atypical antipsychotics","volume":"14","author":"Taylor","year":"2000","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0510","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0920-9964(00)00104-3","article-title":"An open trial of risperidone augmentation of partial response to clozapine","volume":"48","author":"Taylor","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0515","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0006-3223(03)00524-9","article-title":"Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial","volume":"54","author":"Tiihonen","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0520","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4088\/JCP.v66n0808","article-title":"Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial","volume":"66","author":"Tiihonen","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0525","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"d-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0530","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1176\/appi.ajp.157.3.482","article-title":"Gabapentin prophylaxis of clozapine-induced seizures","volume":"157","author":"Usiskin","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0535","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/npp.2010.101","article-title":"Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine","volume":"35","author":"Weiner","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0540","series-title":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis","author":"Wells","year":"2004"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0545","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","article-title":"Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study","volume":"18","author":"Wetzel","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0550","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1192\/bjp.181.3.184","article-title":"Clozapine-resistant schizophrenia: a positive approach","volume":"181","author":"Williams","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0555","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1176\/ajp.153.7.951","article-title":"Time required for initial improvement during clozapine treatment of refractory schizophrenia","volume":"153","author":"Wilson","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0560","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00044011-200626030-00001","article-title":"Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation","volume":"26","author":"Ziegenbein","year":"2006","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0565","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2004-815471","article-title":"Combination of clozapine and amisulpride in treatment-resistant schizophrenia \u2014 case reports and review of the literature","volume":"37","author":"Zink","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0570","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881108089593","article-title":"Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial","volume":"23","author":"Zink","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0575","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200403000-00003","article-title":"The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study","volume":"19","author":"Zoccali","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.08.005_bb0580","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2007.02.009","article-title":"The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study","volume":"93","author":"Zoccali","year":"2007","journal-title":"Schizophr. Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T08:57:11Z","timestamp":1712825831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X11002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0924977X11002045"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.08.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}